• 1
    Colombel J-F, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab treatment results in deep remission for patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND. Gastroenterology. 2010; 138( suppl 1): S158.
  • 2
    O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double blind withdrawal of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978; 2: 955957.
  • 3
    Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996; 347: 215219.
  • 4
    Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol. 1999; 94: 32543257.
    Direct Link:
  • 5
    Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005; 128: 18121818.
  • 6
    Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009; 7: 8085.
  • 7
    Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992; 305: 2022.
  • 8
    Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002; 50: 485489.
  • 9
    Lobel EZ, Korelitz BI, Xuereb MA, et al. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol. 2004; 99: 462465.
    Direct Link:
  • 10
    Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol. 2009; 104: 27602767.
  • 11
    Louis E, Vernier-Massouille G, Grimaud JC, et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors. A prospective ongoing cohort study. Gastroenterology. 2009; 136: A-146.
  • 12
    Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58: 492500.
  • 13
    Waugh AW, Garg S, Matic K, et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Phamacol Ther. 2010; 32: 11291134.
  • 14
    Regueiro M, KKip K, Schraut W, et al. 4.5 yr follow-up of patients enrolled in the randomized controlled trial (RCT) of infliximab (INF) for prevention of postoperative Crohn's disease. Gastroenterology 2010: A542.
  • 15
    Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010; 105: 11421149.
  • 16
    Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005; 52: 2735.
  • 17
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005; 52: 33813390.
  • 18
    Nawata M, Saito K, Nakayamada S, et al. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol. 2008; 18: 460464.
  • 19
    Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010; 69: 12861291.